Avelumab binds PD-L1 on target cells and its IgG1 Fc engages Fcγ receptors on NK cells/macrophages to trigger ADCC (and possibly ADCP), directly killing PD-L1–expressing cells; it also indirectly enhances T‑cell killing via PD‑1/PD‑L1 blockade.